Work

CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy

Year: 2025

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2024.7199

Authors: Anuja V. Abhyankar, Myung-Ju Ahn, Grace K. Dy

Institutions: Roswell Park Comprehensive Cancer Center, Samsung Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408940739

FWCI:

Cites:

Cited by:

Related to: 10